Dengue (DEN) has become the most significant source of arthropod-borne viral disease in humans. Approximately 2.5 billion people (40% of the world's population) live at risk for dengue exposure across the globe, resulting in more than 100 million cases of dengue related illnesses each year. As a result of the increasing frequency of dengue related illnesses, and the introduction of Aedes mosquitos into parts of the United States, DEN is now classified as a Category A pathogen of interest by the National Institutes of Health. Several lines of evidence support a significant role for antibodies during protection from DEN infection and the establishment of immunity following vaccination. However, the presence of DEN antibodies has also been linked to a more severe clinical outcome due to the ability of antibodies to facilitate DEN infection under some circumstances. This antibody dependent enhancement (ADE) of infection poses a significant challenge for the development of a DEN vaccine and highlights the importance of understanding not only the magnitude, but also the breadth, specificity, and persistence of humoral immunity in response to vaccination. The standard method for detecting neutralizing antibodies to dengue viruses is the plaque reduction neutralization test (PRNT). While use of this methodology has allowed for great insight into flavivirus biology and pathogenesis, it has several major limitations. In this proposal, we will develop a novel approach to detecting and measuring antibodies with neutralizing activity present in human sera.
Specific Aim 1 : Construction and evaluation of a DEN replicon.
Specific Aim 2 : Production and characterization of DEN reporter virus particles.
Specific Aim 3 : Evaluation of the utility of DEN reporter virus particles for the detection of neutralizing antibodies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
5R41AI062100-02
Application #
6921928
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (10))
Program Officer
Greenfield, Teri L
Project Start
2004-07-15
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2007-06-30
Support Year
2
Fiscal Year
2005
Total Cost
$495,686
Indirect Cost
Name
Integral Molecular
Department
Type
DUNS #
034055645
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Katzelnick, Leah C; Ben-Shachar, Rotem; Mercado, Juan Carlos et al. (2018) Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. Proc Natl Acad Sci U S A 115:10762-10767
Christian, Elizabeth A; Kahle, Kristen M; Mattia, Kimberly et al. (2013) Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A 110:18662-7
Parameswaran, Poornima; Liu, Yi; Roskin, Krishna M et al. (2013) Convergent antibody signatures in human dengue. Cell Host Microbe 13:691-700
Parameswaran, Poornima; Charlebois, Patrick; Tellez, Yolanda et al. (2012) Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol 86:8546-58
OhAinle, Molly; Balmaseda, Angel; Macalalad, Alexander R et al. (2011) Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 3:114ra128
Narvaez, Federico; Gutierrez, Gamaliel; Perez, Maria Angeles et al. (2011) Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl Trop Dis 5:e1397
Mattia, Kimberly; Puffer, Bridget A; Williams, Katherine L et al. (2011) Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 6:e27252
Gutierrez, Gamaliel; Standish, Katherine; Narvaez, Federico et al. (2011) Unusual dengue virus 3 epidemic in Nicaragua, 2009. PLoS Negl Trop Dis 5:e1394